美国安进地舒单抗注射液使用说明

It is a RANK ligand (RANKL) inhibitor produced by Amgen in the United States. It is also called denosumab, denosumab and other names. It has a different mechanism of action from the currently approved drugs that reduce bone complications of tumors. It is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets nuclear factor-κB receptor activator ligand (RANKL). By preventing RANKL from binding to its receptor substances, it inhibits osteoclast activation and development, reduces bone resorption, and increases bone density.

Desosumab produced by Amgen was approved in the United States in 2010. Its current indication is to prevent bone-related events in patients with bone metastases from solid tumors. It has also been successfully approved for marketing in my country in 2019.

Desosumab is an injection that is relatively complicated to use. Patients need to start treatment under the guidance of a doctor with experience in treatment. Let’s briefly understand its instructions for use.

The recommended dose of denosumab for the prevention of bone-related events in solid tumor bone metastases is 120 mg, administered by subcutaneous injection (upper arm, upper thigh, or abdomen) once every 4 weeks, along with calcium or vitamin D infusion to prevent hypocalcemia. NOTE: Not for use in patients with multiple myeloma for prophylaxis of bone-related events.

For adults or skeletally mature adolescents suffering from unresectable giant cell tumor of bone or surgical resection may cause serious complications, the recommended dose is 120 mg, once every 4 weeks. In the first month of treatment, 120 mg should be added on the 8th and 15th days respectively, and calcium or vitamin D should be infused to prevent hypocalcemia. The recommended dosage for hypercalcemia of malignant tumors is the same as above. Patients need to strictly follow the doctor's advice and use the medication correctly during the treatment process.

Amgen is one of the world's leading biotechnology companies. It is mainly engaged in the exploration, research and development, production and sales of innovative drugs for human use. It is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. The treatment of patients with bone metastases produced by Amgen is of great significance.

Recommended related hot articles: /newsDetail/90967.html